

A29

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 January 2003 (09.01.2003)

PCT

(10) International Publication Number
WO 03/003006 A2

(51) International Patent Classification⁷: **G01N 33/48**

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: **PCT/IB02/03296**

(22) International Filing Date: 28 June 2002 (28.06.2002)

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:
60/301,404 29 June 2001 (29.06.2001) US

(71) Applicants (*for all designated States except US*): **AB SCIENCE [FR/FR]**; 3, avenue George V, F-75008 Paris (FR). **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (EPST) [FR/FR]**; 101, rue de Tolbiac, F-75013 Paris (FR). **UNIVERSITE RENE DESCARTES - PARIS 5 [FR/FR]**; 12, rue de l'Ecole de Médecine, F-75006 Paris (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) [FR/FR]**; 3, rue Michel Ange, F-75016 Paris (FR). **ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS [FR/FR]**; 3, avenue Victoria, F-75010 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MOUSSY, Alain [FR/FR]**; 22 bis, passage Dauphine, F-75006 Paris (FR). **DUBREUIL, Patrice [FR/FR]**; 19, boulevard Piot, F-13008 Marseille (FR). **HERMINE, Olivier [FR/FR]**; 127, avenue du Général Leclerc, F-92120 Palaiseau (FR).

(74) Agents: **MARTIN, Jean-Jacques et al.; Cabinet Régime-beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

Published:

- *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW POTENT, SELECTIVE AND NON TOXIC C-KIT INHIBITORS

(57) Abstract: The present invention relates to a screening method allowing the identification and selection of compounds targeting the transphosphorylase (also called phosphotransferase) domain of c-kit, more particularly compounds selected to be potent inhibitors of constitutively activated c-kit, while being unable to inhibit other activation pathways such as for example the pathways leading to death of IL-3 dependent cells cultured in presence of IL-3.

WO 03/003006 A2

WO 03/003006

PCT/IB02/03296

New potent, selective and non toxic c-kit inhibitors

- 5 The present invention relates to a screening method allowing the identification and selection of compounds targeting the transphosphorylase (also called phosphotransferase) domain of c-kit, more particularly compounds selected to be potent inhibitors of constitutively activated c-kit, while being unable to inhibit other activation pathways such as for example the pathways leading to death of IL-3 dependent cells
10 cultured in presence of IL-3.

The protooncogene c-kit that encodes the receptor for stem cell factor (SCF) belongs to the type III receptor tyrosine kinase subfamily, characterized by the presence of five Ig-like domains in the extracellular domain and by an interkinase sequence that splits the intracytoplasmic domain into the adenosine triphosphate (ATP)-binding domain and the phosphotransferase domain [1] (Figure 1). Its gene is located on chromosome 4q12 in humans and is encoded by the W locus on murine chromosome 5 [2]. The product of the c-kit gene is a transmembrane receptor composed by 976 amino acids (aa), with 519 extracellular aa, a transmembrane domain of 23 aa and an intracellular tail of 433 aa [3].
15 The c-kit receptor is normally expressed on various cell types including melanocytes, mast cells, primitive hematopoietic cells, primordial germ cells and interstitial cells of Cajal (ICC) [4]. The ligand for c-kit receptor is a cytokine named stem cell factor (SCF) or Kit ligand (KL), or Steel factor (SL) or mast cell growth factor (MCGF) [5, 6]. This cytokine is encoded by a gene located on chromosome 12 in human and by the Sl locus on murine chromosome 10 [7]. The product of this gene is alternatively spliced, leading
20 to a soluble form and/or to a membrane-anchored form [8]. SCF acts either alone or in combination with other growth factors in promoting the survival and self-renewal of stem cells, and the proliferation, differentiation and migration of various cell types :
25

WO 03/003006

PCT/IB02/03296

2

melanocytes, mast cells, primitive hematopoietic cells, germ cells, and ICC. SCF binding to its receptor promotes dimerization of c-kit and induces intrinsic tyrosine kinase activity, resulting in transphosphorylation of particular tyrosine residues [9, 10]. When phosphorylated, these tyrosine residues become docking sites for several intracellular 5 signaling molecules, leading to various cellular responses in different cell types.

However, like it is the case for a number of other kinases, c-kit can be activated without binding its ligand SCF. A number of naturally occurring mutations lead to constitutive activation of the c-kit kinase that results in abnormal cell proliferation and the 10 development of diseases such as mastocytosis and various other cancers.

The first activating mutation of c-kit was described in a feline model, induced by the Hardy-Zuckerman 4-feline sarcoma virus encoding the transforming oncogene v-kit, a mutated and truncated viral homologue of c-kit [11]. Recently, receptor mutations leading to constitutive activation of c-kit have been described in mast cell leukemic cell 15 lines and in cells derived from patients with mastocytosis, associated or not with others hematological malignancies. The various activating mutations of c-kit that have been identified so far are described below in details.

A second mechanism leading to an increased activation of c-kit is autocrine secretion of 20 SCF in various tumoral tissues, as in small cell lung cancer (SCLC) [12], colorectal carcinoma [13], breast carcinoma [14], gynecological tumors [15], and neuroblastomas [16].

Tyrosine kinase inhibitors, which have been proposed in the art to inhibit c-kit have not 25 been developed or shown to inhibit activated-mutant c-kit. There are two exceptions detailed below, one of which (STI 571) is not active with our assay, and we will provide here an explanation for the mistaken interpretation of the authors, and the other SU6577 is only active at high concentration at which toxicity is seen.

WO 03/003006

PCT/IB02/03296

3

Heinrich et al. (2000, Blood, Aug 1;96(3):925-32) state that STI 571 (WO 99/03854) has a more potent inhibitory effect on the kinase activity of a mutant in a human mast cell leukemia cell line (HMC-1, expressing a juxtamembrane mutation), than it does on ligand-dependent activation of the wild-type receptor. As a result, this compound could 5 appear useful for treating proliferative diseases involving the activated mutant c-kit but not diseases caused by ligand activated c-kit.

The present invention goes to the opposite direction since the method described in details below is directed to the identification of compounds that are capable of inhibiting 10 activated c-kit whether they are SCF activated c-kit or mutant activated c-kit.

Furthermore, as mentioned above, results presented in Heinrich et al., 2000 are contrary to those obtained in connection with the invention. The present invention describes a method directed at the identification of compounds capable of inhibiting constitutively 15 activated c-kit. With this method, we were able to show that STI 571 is an inhibitor of c-kit wild but do not act on mutant activated c-kit such as the D816 mutant.

The general problem underlying the present invention is therefore to define a screening method allowing the identification and selection of non-toxic compounds capable of 20 inhibiting c-kit, whether they are SCF-activated c-kit inhibitors, constitutively activated c-kit inhibitors or both.

Indolinone derivatives such as SU4984, SU6663, SU6577 and SU5614 have been tested for c-kit inhibition by Yongsheng Ma and B. Longley, Feb 2000 ; Indolinone derivatives 25 inhibit constitutively activated KIT mutants and kill neoplastic mast cells, The Society For Investigative Dermatology, vol 114, no2, pages 392-394. It is shown in this publication that among the compound tested, only SU6577 at 40 μ M could substantially reduce receptor phosphorylation of the D816 mutant activated c-kit. This compound is

WO 03/003006

PCT/IB02/03296

4

also active on c-kit wild, but at a 40 µM concentration, the problem is that the activity of SU6577 on the D816 mutant might result from toxicity. A lack of specificity on c-kit versus other tyrosine kinases would render such a compound inadequate for therapeutic purposes.

5

In this regard, the method contemplated by the invention provides a second testing on IL-3 dependent cells cultured in presence of IL-3. Candidate compounds that are effective against activated c-kit are readily cross-checked for their specificity and toxicity.

10

Many different compounds have been described as tyrosine kinase inhibitors, for example, bis monocyclic, bicyclic or heterocyclic aryl compounds (WO 92/20642), vinylene-azaindole derivatives (WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (US 5,330,992), Styryl compounds (US 5,217,999), styryl-substituted pyridyl compounds (US 5,302,606), seleoindoles and selenides (WO 94/03427), tricyclic polyhydroxylic compounds (WO 92/21660) and benzylphosphonic acid compounds (WO 91/15495), pyrimidine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504, US 5,883,116, US 5,883,113, US 5,886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940) and aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758).

25 None of these compounds, however, have been demonstrated to selectively inhibit activated c-kit, while being potent inhibitors of c-kit wild acting in the transphosphorylation domain and unable to promote death of IL-3 dependant cells cultured in presence of IL-3.

WO 03/003006

PCT/IB02/03296

We further show here that specifically targeting the transphosphorylase or the juxtamembrane domain of c-kit is of interest. Indeed, mutations or deletions in these domains results in constitutively activated c-kit. For example, among compounds 5 selected to be active on the D816 mutant as well as on SCF activated c-kit wild; some have been found in connection with the invention to be highly potent c-kit wild inhibitors.

Description

10

Therefore, the present invention relates to a screening method for identifying compounds that are selective and potent inhibitors of c-kit, which comprises :

- a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,
- 15 b) selecting compounds that inhibit activated c-kit,
- c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependant cells cultured in presence of IL-3.

In frame with the invention, the expression "activated c-kit" means a constitutively 20 activated-mutant c-kit including at least one mutation selected from point mutations, deletions, insertions, but also modifications and alterations of the natural c-kit sequence (SEQ ID N°1). Such mutations, deletions, insertions, modifications and alterations can occur in the transphosphorylase domain, in the juxtamembrane domain as well as in any domain directly or indirectly responsible for c-kit activity. The expression "activated c- 25 kit" also means herein SCF-activated c-kit. In a preferred embodiment, the activated-mutant c-kit in step a) has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants. In another preferred

WO 03/003006

PCT/IB02/03296

6

embodiment, the activated-mutant c-kit in step a) has a deletion in the juxtamembrane domain of c-kit. Such a deletion is for example between codon 573 and 579 amino acids called c-kit d(573-579). The point mutation V559G proximal to the juxtamembrane domain c-kit is also of interest.

5

The screening method can further comprise the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit (for example in the transphosphorylase domain), which are capable of inhibiting SCF-activated c-kit wild.

10 Alternatively, in step a) activated c-kit is SCF-activated c-kit wild.

A best mode for practicing this method consists of a testing at a concentration above 10 μM in step a). Relevant concentrations are for example 10, 15, 20, 25, 30, 35 or 40 μM .

15 In step c), IL-3 is preferably present in the culture media of IL-3 dependant cells at a concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

Examples of IL-3 dependant cells include but are not limited to cell lines naturally expressing and depending on c-kit for growth and survival. Among such cells, human mast cell lines can be established using the following procedures :

20 For example, normal human mast cells can be infected by retroviral vectors containing sequences coding for a mutant c-kit comprising the c-kit signal peptide and a TAG sequence allowing to differentiate mutant c-kits from c-kit wild expressed in hematopoetic cells by means of antibodies.

This technique is advantageous because it does not induce cellular mortality and the 25 genetic transfer is stable and gives satisfactory yields (around 20 %). Pure normal human mast cells can be routinely obtained by culturing precursor cells originating from blood obtained from human umbilical vein. In this regard, heparinized blood from umbilical

WO 03/003006

PCT/IB02/03296

vein is centrifuged on a Ficoll gradient so as to isolate mononucleated cells from other blood components. CD34+ precursor cells are then purified from the isolated cells mentioned above using the immunomagnetic selection system MACS (Miltenyi biotech). CD34+ cells are then cultured at 37°C in 5 % CO₂ atmosphere at a concentration of 10⁵ 5 cells per ml in the medium MCCM (α-MEM supplemented with L-glutamine, penicillin, streptomycin, 5 10⁻⁵ M β-mercaptoethanol, 20 % veal foetal serum, 1 % bovine albumin serum and 100 ng/ml recombinant human SCF. The medium is changed every 5 to 7 days. The percentage of mast cells present in the culture is assessed each week, using May-Grünwald Giemsa or Toluidine blue coloration. Anti-tryptase antibodies can also be 10 used to detect mast cells in culture. After 10 weeks of culture, a pure cellular population of mast cells (< 98 %) is obtained.

It is possible using standard procedures to prepare vectors expressing c-kit for transfecting the cell lines established as mentioned above. The cDNA of human c-kit has been described in Yarden et al., (1987) EMBO J.6 (11), 3341-3351. The coding part of 15 c-kit (3000 bp) can be amplified by PCR and cloned, using the following oligonucleotides :

- 5'AAGAAGAGATGGTACCTCGAGGGTGACCC3' (SEQ ID No2) sens
- 5'CTGCTTCGCGGCCGCGTTAACTCTTCAACCA3' (SEQ ID No3) antisens

The PCR products, digested with Not1 and Xho1, has been inserted using T4 ligase in 20 the pFlag-CMV vector (SIGMA), which vector is digested with Not1 and Xho1 and dephosphorylated using CIP (Biolabs). The pFlag-CMV-c-kit is used to transform bacterial clone XL1-blue. The transformation of clones is verified using the following primers :

- 5'AGCTCGTTAGTGAACCGTC3' (SEQ ID No4) sens,
- 5'GTCAGACAAAATGATGCAAC3' (SEQ ID No5) antisens.

WO 03/003006

PCT/IB02/03296

8

Directed mutagenesis is performed using relevant cassettes is performed with routine and common procedure known in the art..

The vector Migr-1 (ABC) can be used as a basis for constructing retroviral vectors used for transfecting mature mast cells. This vector is advantageous because it contains the sequence coding for GFP at the 3' end of an IRES. These features allow to select cells infected by the retrovirus using direct analysis with a fluorocytometer. As mentioned above, the N-terminal sequence of c-kit c-DNA can be modified to introduce a Flag sequence that will be useful to discriminating exogenous from endogenous c-kit.

- 10 Other IL-3 dependent cell lines that can be used include but are not limited to:
- BaF3 mouse cells expressing wild-type or mutated form of c-kit (in the juxtamembrane and in the catalytic sites) are described in Kitayama et al, (1996), Blood 88, 995-1004 and Tsujimura et al, (1999), Blood 93, 1319-1329.
 - IC-2 mouse cells expressing either c-kit^{WT} or c-kit^{D814Y} are presented in Piao et al, 15 Proc. Natl. Acad. Sci. USA 93, 14665-14669.

IL-3 independent cell lines are :

- HMC-1, a factor-independent cell line derived from a patient with mast cell leukemia, expresses a juxtamembrane mutant c-kit polypeptide that has constitutive kinase activity 20 (Furitsu T et al, J Clin Invest. 1993;92:1736-1744 ; Butterfield et al, Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345-355 and Nagata et al, Proc Natl Acad Sci U S A. 1995;92:10560-10564).
- P815 cell line (mastocytoma naturally expressing c-kit mutation at the 814 position) has been described in Tsujimura et al, (1994), Blood 83, 2619-2626.

WO 03/003006

PCT/IB02/03296

The extent to which component (ii) inhibits activated c-kit can be measured *in vitro* or *ex vivo*. In case it is measured *ex vivo*, cell lines as prepared or listed above expressing an activated-mutant c-kit, which has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants, are preferred.

In another preferred embodiment, the method further comprises the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration below 10 μM . This can be measured *in vitro* or *ex vivo*. Examples of cell lines expressing c-kit include but are not limited to : mast cells, transfected mast cells, HMC-1, BaF3, P815, and IC-2.

Therefore, compounds are identified and selected according to the method described above are potent, selective and non-toxic c-kit wild inhibitors. It is also worth noting that said inhibitors act on the transphosphorylation domain of c-kit wild.

In a further embodiment, the invention is directed to a screening method for identifying compounds that are selective and potent inhibitors of c-kit, which comprises :

20 i) addition of chemical groups responsible for the inhibition of c-kit autophosphorylation to compounds identified by the method depicted above, wherein activated c-kit is SCF-activated c-kit wild,

ii) testing and selecting a subset of compounds identified in step i), which inhibit activated-mutant c-kit as defined above, such as mutants in the transphosphorylase 25 domain.

Alternatively, the screening method according to the invention can be practiced *in vitro*. In this regard, the inhibition of mutant-activated c-kit and/or c-kit wild can be measured

WO 03/003006

PCT/IB02/03296

10

using standard biochemical techniques such as immunoprecipitation and western blot. Preferably, the amount of c-kit phosphorylation is measured.

In a still further embodiment, the invention contemplates a screening method as described above for identifying potent and selective compounds that are inhibitors of c-kit comprising :

- a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an IC₅₀ < 10 μM, by measuring the extent of cell death,
 - b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,
 - c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an IC₅₀ < 10 μM, preferably an IC₅₀ < 1 μM, by measuring the extent of cell death.
- Here, the extent of cell death can be measured by ³H thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide. These are common techniques routinely practiced in the art.

Compounds that are intended to be screened can be tyrosine kinase inhibitors. Many different compounds have been described as tyrosine kinase inhibitors, for example, bis monocyclic, bicyclic or heterocyclic aryl compounds (WO 92/20642), vinylene-azaindole derivatives (WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (US 5,330,992), Styryl compounds (US 5,217,999), styryl-substituted pyridyl compounds

WO 03/003006


PCT/IB02/03296

II

(US 5,302,606), seleoindoles and selenides (WO 94/03427), tricyclic polyhydroxylic compounds (WO 92/21660) and benzylphosphonic acid compounds (WO 91/15495).

Therefore, the invention relates to a screening method as defined above, wherein said compounds are selected from the group consisting of indolinone, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

Among preferred compounds to be tested according to the method of the invention, it is of interest to focus on pyrimidine derivatives such as N-phenyl-2-pyrimidine-amine derivatives of formula I :



15


wherein the R1, R2, R3, R13 to R17 groups have the meanings depicted in EP 564 409 B1, incorporated herein in the description.

Preferably, the N-phenyl-2-pyrimidine-amine derivative is selected from the compounds corresponding to formula II :

WO 03/003006

PCT/IB02/03296

12




Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;

- 5 R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;
and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function.


For example R7 can be :

10



Among these compounds, the preferred are defined as follows :

- R1 is a heterocyclic group, especially a pyridyl group,
R2 and R3 are H,
15 R4 is a C1-C3 alkyl, especially a methyl group,
R5 and R6 are H,
and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, for example the group :



20

WO 03/003006

PCT/IB02/03296

13

The preparation of such compounds is described in example 21 of EP 564 409.

Alternatively, the screening may be performed with indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504), US 5,883,116, US 5,883,113, US 5,886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940), 4-amino-substituted quinazolines (US 3,470,182), 4-thienyl-2-(1H)-quinazolones, 6,7-dialkoxyquinazolines (US 3,800,039), aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758), 4-anilinoquinazoline compounds (US 4,464,375), and 4-thienyl-2-(1H)-quinazolones (US 3,551,427).

So, preferably, the invention also relates to a screening method as defined above, wherein said compounds are :

- 15 - pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives.
- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- monocyclic, bicyclic aryl and heteroaryl compounds,
- or quinazoline derivatives.
- 20 The invention is also directed to a compound obtainable by the method as depicted above, wherein said compound is a selective and potent inhibitor of activated c-kit, a potent inhibitors of c-kit wild acting in the transphosphorylation domain and is unable to promote death of IL-3 dependant cells cultured in presence of IL-3.
- The invention also embraces the use of said compound to manufacture a medicament.

25 Utility of the invention will further ensue from the detailed description of molecular mechanisms of signal transduction via c-kit and mutated c-kit that are implicated in numerous diseases.

WO 03/003006

PCT/IB02/03296

14

SIGNAL TRANSDUCTION INDUCED BY ACTIVATION OF NORMAL C-KIT.

SCF is an essential growth factor in hematopoiesis since it synergizes with almost all the hematopoietic growth factors, except M-CSF, to induce *in vitro* hematopoiesis [17]. This
5 factor is produced by bone marrow stromal cells, and acts through interaction with its receptor, c-kit [18]. As previously noticed, the c-kit receptor is a glycoprotein of 145 kDa and belongs to the type III tyrosine kinase subfamily, characterized by the presence of five Ig-like domains in the extracellular part of the molecule and by an interkinase sequence that splits the intracytoplasmic domain into the adenosine triphosphate (ATP)-
10 binding domain and the phosphotransferase domain [1]. C-kit is strongly expressed by CFU-GEMM, BFU-E and by progenitors and mature cells of the mast cell lineage [19].

Ligand binding to c-kit results in activation of the catalytic function, resulting in autophosphorylation of tyrosine residues of the cytoplasmic domain. These
15 phosphotyrosine residues become docking sites for various cytoplasmic signaling molecules containing SH2 domain. C-kit activates canonical signal transduction pathways common to many growth factor receptors, including those depending on PI3-kinase, ras and JAK2. Molecules known to associate with c-kit *in vivo* or *in vitro* include p85 subunit of PI3-kinase, multiple Src family members, Lyn and Fyn, Vav, Grb2, SHP-
20 1, SHP-2, PKC, MATK (CHK) and Socs1, while there are divergent data concerning PLC- γ , GTPase activating Protein of ras (GAP) and JAK2. Additional molecules are activated or phosphorylated in response to c-kit activation : Shc, Tec, Vav GDP/GTP exchange factor, raf-1, MAPK, Akt, CRKL, p120 Cbl, and Doc. Recent studies performed in various cell systems have yielded divergent results regarding the substrates
25 that associate with and are phosphorylated by c-kit. These discrepancies might reflect either differences in experimental methods or functionally relevant variations in substrate expression profiles of individual cell types, which could be the basis of distinct signals and cell type specific responses mediated by the same ligand/receptor system. For

WO 03/003006

PCT/IB02/03296

15

these reasons, we choose to describe the data obtained regarding c-kit signaling in various cellular contexts.

- The first initiator of signalization is the ligand induced-dimerization of c-kit, which induces intrinsic tyrosine kinase activity of c-kit, resulting in transphosphorylation at critical tyrosine residues [10]. Moreover, in response to ligand stimulation, c-kit appears to be phosphorylated on serine residues by PKC, which inhibits c-kit autophosphorylation [20].
- One of the most efficient associations with c-kit, observed in various cell types, is contracted by SH2 domain of p85 subunit of PI3-kinase [21, 22] via the phosphorylated tyrosine residue 719 of murine c-kit or tyrosine 721 of human c-kit [23]. C-kit signalisation has been studied in human hematopoietic cells, mainly in MO7e and CMK, two megakaryocytic cell lines (Table 1 below).

15 **Table 1 : Molecules interacting with the intracellular portion of the human c-kit and/or activated in response to SCF.**

Molecules	Human cells	References
Akt	293, U2OS, BHX21, HeLa	[82]
c-Cbl	MO7e, TF-1	[79, 80]
CRKL	MO7e	[81]
Doc	MO7e	[86]
p125 Fak	TF-1	[94]
Fyn	MO7e	[127]
Grap	MO7e, TF-1, K562	[78]
Jak2	MO7e, TF-1	[87, 88]

WO 03/003006

PCT/IB02/03296

16

Lyn	MO7e, Normal progenitors	[128]
MAPK	melano 501 mel	[93]
MATK (CHK)	CMK	[84, 127]
PI3-K	293, U2OS, BHX21, HeLa	[82, 91]
PLC- γ	MO7e	[99]
Raf1	MO7e	[77]
Ras	MO7e	[77]
SHP-1	MO7e	[97]
SHP2 (Syp)	MO7e	[77]
Tec	MO7e	[83]
Vav	MO7e, TF-1	[85]

In these cells, SCF induces activation and/or recruitment of major kinases such as PI3-kinase, Src kinases (Fyn and Lyn) and JAK2, and various adaptors molecules, Grb2, Grap, Vav, CRKL via their SH2 domain. These events result in formation of various molecular associations via SH2, SH3 or PH domains, which in turn start activation of different pathways. Ras pathway was showed to be activated in response to SCF stimulation, leading to interaction between Ras and Raf-1, thus initiating MAPKinase cascade [24]. Indeed, Grap, an adaptor molecule, interacts with ligand-activated c-kit through its SH2 domain and is associated with a ras guanine nucleotide exchange factor, mSos1, through its SH3 domain, coupling signals from receptor and cytoplasmic tyrosine kinase to the ras signaling pathway [25]. Another adaptor molecule related to Grap, Grb2, interacting via its SH2 domain with a phosphorylated tyrosine residue of c-kit, may recruit c-Cbl and Shc [26, 27]. After activation, kinase may either play the role of adaptor molecule such as PI3-kinase interacting with c-Cbl and CRKL [28], or the role of kinase such as PI3-kinase phosphorylating Akt [29]. In few cases, interaction

WO 03/003006

PCT/IB02/03296

17

- and/or activation is described without connection with any known signaling pathway. This is the case for Tec [30], MATK [31], Vav [32] and Doc [33]. Unexpectedly, JAK-STAT pathway is poorly described during c-kit activation. JAK2, a cytosolic tyrosine kinase essential for non tyrosine kinase cytokine receptor superfamily signaling, has
5 been described physically associated with c-kit, prior to ligand activation, and phosphorylated on tyrosine residues in response to SCF [34-36], or not associated with c-kit [30]. In addition, SCF activates cytosolic transcription factors like STAT1 in MO7e cell line [37].
- 10 C-kit signalisation has been also examined in various non hematopoietic human cell lines. Blume-Jensen et al. demonstrated that SCF induced activation of Akt and mediated phosphorylation of Serine residue 136 of Bad in a PI3-kinase-dependent manner [29]. *In vitro* experiments performed on embryonic fibroblasts indicate that PI3-kinase and PLC- γ compete for association with tyrosine residue 721 of human c-kit, with
15 p85/PI3-kinase exhibiting higher affinity [38]. In H526 cell line (Small cell lung carcinoma, SCLC), SCF induced activation of Src-kinase, Lck, and its interaction with the juxtamembrane domain of c-kit [39]. In 501 mel, a human melanoma cell line, Hemesath et al. described that SCF stimulation resulted in activation of MAPK which, in turn, phosphorylated transcription factor microphthalmia (Mi), upregulating Mi
20 transactivation via interaction with p300/CBP [40].

Interestingly, interconnection between c-kit and integrin signaling pathways was observed in TF-1 cell line [94]. SCF induces spreading of fibronectin-adherent TF-1 cells and enhances tyrosine phosphorylation of pp125 FAK in a dose-dependent manner,
25 when compared to the level of tyrosine phosphorylation of pp125 FAK in the absence of SCF. These effects depend on a worthmannin-, integrin activation- sensitive pathways.

WO 03/003006

PCT/IB02/03296

18

Regarding c-kit deactivation, two main pathways have been described in different cellular contexts. In hematopoietic cells, one pathway involves SHP-1, a tyrosine phosphatase, interacting with c-kit probably at 569 tyrosine phosphorylated residue, which down-regulates tyrosine residue phosphorylation state of c-kit. [42-45]. The role 5 of phosphatase SHP-2 (Syp) is less clear. It has been shown that SHP-2 associated with activated c-kit in MO7e cell line via its SH2 domain, became phosphorylated and complexed with Grb2 [24]. This connection to Grb2 could lead to ras/MAPkinase pathway activation and to cell proliferation. By contrast, it has been shown, in BA/F3 cells expressing c-kit, that SHP-2 association to c-kit Y567F is markedly reduced. In this 10 case, an hyperproliferative response to SCF was observed, suggesting that SHP-2 downregulates SCF-induced proliferation [45].

Activation and deactivation of human c-kit have been also studied in porcine endothelial cells (PAE) (Table 5). Activation of PI3-kinase, PLC- γ and Raf/MAPKinase cascade 15 was described in response to SCF in PAE cells transfected with human c-kit [46]. In these cells, a first negative feedback loop is the PI3-K, PLD and PKC pathway which leads to phosphorylation at 741 and 746 serine residues of c-kit [47]. A second deactivation pathway is PI3-kinase-induced PLD activation and phosphatidylcholine (PtdCho)-specific phospholipase D activation, (PtdCho)-PLD, that generated 20 phosphatidic acid (PtdH), metabolized into diacylglycerol (DAG), an activator of PKC and a precursor of arachidonic acid (D4Ach) [48]. These authors also showed that SCF induced PLA2 activation, a second pathway generating D4Ach.

In murine bone marrow-derived mast cells (BMMC), it has been demonstrated that SCF 25 induces i) PI3-kinase activation, which in turn stimulates Rac-1 and Jnk pathway [49] and ii) binding and phosphorylation of Src kinases Fyn on tyrosine 567 [49] and Lyn [50]. In rat mast cells isolated from the peritoneal cavity, Koike et al. have shown that SCF induced PLD activation and subsequent release of D4Ach through the protein

WO 03/003006

PCT/IB02/03296

19

tyrosine kinase pathway and without activation of the phosphoinositide-specific PLC- γ [51, 52]. In these cells, Nagai et al. have shown the involvement of PI3-kinase, protein tyrosine kinase (PTK) and myosin light chain kinase in SCF induced histamine release [53]. Regarding c-kit deactivation in murine cells, another way to decrease SCF signal is 5 the down-modulation of c-kit expression. Yee et al. and Miyazawa et al. have shown that c-kit internalization and ubiquitination is dependent on intact kinase activity of c-kit [54, 55]. In BMMC, c-kit activates PLC- γ resulting in the hydrolysis of PI4,5 diP into DAG and inositol-1,4,5 triP inducing mobilization of intracellular Ca⁺⁺ [56]. This calcium influx seems to be critical for c-kit internalization. Moreover, in the absence of PI3- 10 kinase activation, the c-kit receptor internalizes but remains localized near the inner side of the plasma membrane. Of note, c-kit internalization is completely prevented when both PI3-kinase and Ca⁺⁺ influx are inhibited [56]. A novel mediator of downregulation of c-kit-dependent mitogenesis could be Socs-1 (Suppressor of cytokine signaling) [57]. SCF induces synthesis of Socs-1, that binds to c-kit via its SH2 domain. The mechanism 15 of Socs-1 activity seems to involve its interaction with Grb2 and the negative regulatory N-terminus of Vav [58].

MOLECULAR DYSFUNCTIONS RELATED TO C-KIT MUTATIONS

c-kit mutations found in humans affect phosphotransferase domain near Y823 site of 20 autophosphorylation. However, studies concerning molecular dysfunctions of c-kit mutants revealed that mutations alter various aspects of c-kit metabolism : dimerization, signaling, enzyme expression and internalization.

C-kit receptor dimerization

25 The c-kit receptor dimerization is a key event in signal transduction, and takes place before tyrosine phosphorylation. A sequential model of c-kit activation is proposed by Blechman et al. [58]. Monovalent SCF binding exposes a putative receptor site that facilitates rapid dimerization of the receptor, further stabilized by binding of the second

WO 03/003006

PCT/IB02/03296

20

arm of the dimeric SCF molecule. Ligand binding site seems to be confined to the three N-terminal Ig-like domains, and dimer formation seems to be mediated by the fourth Ig-like domain [10, 58]

5 Thus, modifications of c-kit can alter either the dimerization domain or the transduction domain of this receptor. Tsujimura et al. [59] and Kitayama et al. [60] have performed cross-linking analysis of various c-kit receptors, wild type and mutated variants, to determine whether the constitutively activated c-kit leads to receptor dimerization or not, in the absence of SCF. They have respectively studied four forms of c-kit : c-kit^{WT}, c-
10 kit^{d(573-579)} (c-kit with a deletion from codon 573 to 579), c-kit^{V559G} or c-kit^{D814V} that were introduced in Ba/F3 cells. SCF induces tyrosine phosphorylation of c-kit^{WT} that is detected at an approximate molecular weight of 330 kDa, representing a complex containing cross-linked homodimer of c-kit^{WT} and SCF. After treatment with SCF, the phosphorylated forms of c-kit^{d(573-579)} and c-kit^{V559G} are detected with a molecular
15 mass of 330 kDa, as for c-kit^{WT}. In the absence of SCF, an abundant tyrosine phosphorylation of c-kit^{d(573-579)} and c-kit^{V559G} is observed and corresponds to a 290 kDa cross-linked homodimer of the c-kit mutant. By contrast, in the absence of SCF, constitutively phosphorylated c-kit^{D814V} is scarcely detectable as a 290 kDa dimeric form, whereas a 330 kDa that represents a cross-linked complex, containing homodimer
20 of c-kit^{D814V} and SCF, is observed after stimulation with SCF. These data suggest that an activating deletion, such as c-kit^{d(573-579)}, or an activating mutation, such as the c-
kit^{V559G}, that take place in the juxtamembrane domain are able to induce a constitutive dimerization of c-kit in the absence of SCF stimulation, whereas an activating mutation at the catalytic kinase domain (c-kit^{D814V}) causes constitutive activation of c-kit
25 without dimerization.

WO 03/003006

PCT/IB02/03296

21

Nevertheless, Tsujimura et al. have reported contrasting data concerning the mechanism of c-kit^{D814V} or c-kit^{D814Y} constitutive activation [61]. Indeed, they found that a truncated form of this variant receptor, devoid of extracellular domain, was 5 constitutively activated and capable of conferring factor-independent growth to murine IL-3-dependent Ba/F3 cells, whereas equivalent truncation of wild type c-kit was unable to do so, suggesting that extracellular domain is not involved in the constitutive activation of c-kit^{D814Y} or c-kit^{D814V}. Moreover, these authors presented data indicating that c-kit^{D814V} may not function as a monomeric form. They observed that 10 extracellular domain-truncated c-kit^{D814V} coimmunoprecipitated with full length wild-type receptor or c-kit^{W42}, a dominant negative receptor. These authors proposed that self-association of c-kit^{D814Y} or c-kit^{D814V} might result from the mutation itself by creating a novel receptor self-association domain.

15 *Signaling alterations*

Concerning c-kit^{D814Y}, Piao et al. [62] have investigated the mechanism of oncogenic activation by this mutation in the murine mast cell line IC2, expressing either c-kit^{WT} or c-kit^{D814Y}.

20 In this cell line, expression of c-kit^{D814Y} altered c-kit signaling when compared to c-kit^{WT} [62]. C-kit^{D814Y} mutation introduced changes in the substrate recognition of c-kit, as observed in the pattern of receptor autophosphorylation sites, the pattern of tyrosine phosphorylated proteins and the selectivity of the mutated receptor for synthetic peptidic substrates. This is relevant to the fact that this mutation changes a residue 25 conserved in the receptor tyrosine kinase family (RTK) into a residue conserved in the non receptor tyrosine kinase family (NRTK), including c-Abl. Then, this mutation might

WO 03/003006

PCT/IB02/03296

22

alter receptor conformation to favor interaction with group I SH2 domain, relevant substrates for NRTK [63, 64]. One novel substrate could be the 130 kDa protein detected by these authors. Moreover, given the fact that SHP-1 desactivates c-kit, c-kit^{D814Y} mutation might alter one way of c-kit deactivation by increasing the rate of SHP-1 Ub-
5 mediated proteolysis, since SHP-1 is absent in c-kit^{D814Y} expressing cells. In fact, a peptide inhibitor of the proteolytic pathway, LLnL, stabilizes SHP-1 and prevents its degradation. So, two main arguments could explain the expansion of IC2/c-kit^{D814Y} cells in the absence of any growth factors : the constitutive kinase activity of the mutant c-kit^{D814Y} and the enhanced degradation of SHP-1. Whatsoever, the authors have not
10 presented data suggesting that c-kit^{D814Y} activation is more prolonged than that of c-kit^{WT}. To argue the fact that the mutation c-kit^{D814Y} might alter the fidelity of c-kit signaling, one could notice the parallel between this mutation and the mutation M918T of Ret, found in 95% of multiple endocrine neoplasia type 2B (NEM 2B) [65]. Ret is another tyrosine kinase receptor belonging to PDGF receptor family in which M918 is
15 highly conserved.[66, 67]. Interestingly, in other tyrosine kinase receptor family, there is a threonine at equivalent codon, suggesting that M918T mutation induces alteration in substrat affinity or affinity for new substrat .

Enzymatic functions and c-kit mutations

20 SHP-1 expression is different in IC2/c-kit^{WT} and IC2/c-kit^{D814Y} cells, and this is also the case for other proteins like MMCP-4 and MMCP-6, that are proteases present in the granules of murine mast cells and differentially expressed at various stages of mast cell maturation. Indeed, MMCP-6 transcripts are expressed at low level in IC2/c-kit^{WT} cells in the presence of exogenous SCF, and this level increases as the result of c-kit^{D814Y} expression. MMCP-4 transcripts are not detectable by RT-PCR in IC2/c-kit^{WT} cells, but
25 are abundantly expressed in IC2/c-kit^{D814Y} cells. The differences observed between the

WO 03/003006

PCT/IB02/03296

23

wild form and the mutant suggest that the signals transduced by c-kit^{WT} stimulated by SCF and by c-kit^{D814Y} are not equivalent : the mutation c-kit^{D814Y} alters not only the proliferation of mast cells but also their stage of maturation.

5 *Receptor internalization and c-kit mutations*

Downregulation of the internalization signal can take part in the prolonged activation of c-kit, since internalization is known to serve as an attenuation mechanism for receptor signaling. In fact, studies on the kinetics of degradation of c-kit receptor showed that without SCF, the surface c-kit^{d(573-579)} decreases barely, whereas when FMA3 cells
10 are incubated with SCF, the surface c-kit^{d(573-579)} decreases remarkably. By contrast, the activated c-kit^{D814V} receptor is continuously degraded, even in the absence of SCF [68]. Since calcium metabolism and PI3-kinase activity were described as mediators of c-kit internalization [54-56], it will be interesting to study these pathways in cells expressing c-kit^{d(573-579)}, c-kit^{V559G}, or c-kit^{D814V}.

15

Example 1 : Methodology / Experimental approaches

First step : cellular proliferation to select molecules which are able to slowdown or stop cellular growth induced by c-kit activation. Here, SCF activated c-kit is used.

20 Then, the effect of these molecules is analyzed by biochemistry techniques (immuno precipitations and western-blots), so that to determine if the inhibitor acts directly on the receptor c-kit or on other proteins, which are mediators of Kit signals. In a second step, a subset of molecules identified is selected in a cellular test on IL-3 dependant cells cultured in presence of IL-3. molecules that are not toxic are identified as potent specific
25 c-kit inhibitors for a use in therapy.

WO 03/003006

PCT/IB02/03296

24

Example 2 : Cellular models

Two types of cell lines carrying wild or mutated forms of c-kit are available : lines derived from mastocytomes and the Ba/F3 cell model (cells depending on IL-3). In the 5 Ba/F3 cells, the expression of c-kit removes the dependence vis-a-vis IL-3. Consequently, cDNA of wild or mutated murine c-kit has been introduced and these cells proliferate either in presence of SCF in case of c-kit wild or in absence of any growth factor in case of activated mutant c-kit.

Preparation of cell lines :

- 10 - **Ba/F3-Kit** : Ba/F3 cells in which Kit gene, mutated or wild, has been introduced.

They proliferate either in presence of Kit ligand (SCF) or in presence of IL-3.

Juxtamembrane mutations

- **Ba/F3- Kit Δ 27** (transfected juxtamembrane mutation– identified at the Laboratory)
15 - **Ba/F3-KitG559** (transfected juxtamembrane mutation)
- **FMA3** (deletion 7aa. juxtamembrane identified in a mouse mastocytome)

Mutation in the kinase domain (residue 814)

- **IC2** (murine mast cell line which does not express endogenous c-kit) transfected with
20 the 814 mutated c-kit
- **P815** (murine mastocytoma cell line expressing an endogenous c-kit carrying the 814V mutation).

Example 3 : Study of STI 571 on c-kit wild and mutant activated c-kit.

25

The inhibitor of oncogene BCR-ABL, STI 571, is also an inhibitor of PDGF receptor,
which is related to c-kit. Consequently, the STI 571 has been tested on Kit.

WO 03/003006

PCT/IB02/03296

25

2.1 Effect of STI 571 on cellular proliferation induced by c-kit (Figure 1).

For these experiments, IL-3 is used as a control to determine toxic doses of the inhibitor. At doses inferior to toxicity level (< 10 μ M), we found that STI 571 inhibits totally the proliferation depending on c-kit in case of c-kit wild and of juxtamembrane mutations (Δ27, FMA3) but not the proliferation of cells carrying 814 mutation (IC2 and P815).

2.2 Effect of STI 571 on activated c-kit (Figure 2)

The first step of c-kit activation consists of receptor phosphorylation on tyrosine residues. Thus, the phosphorylation state is a measure of receptor activation. By using specific antibodies, c-kit has been isolated by immunoprecipitation and c-kit phosphorylation has been determined using common procedures. The STI 571 considerably reduces the phosphorylation of c-kit wild and of c-kit bearing juxtamembrane mutations. On the contrary, the phosphorylation of the 814 mutant c-kit is not reduced by the STI 571.

15

Conclusion : STI 571 is a new inhibitor very efficient on c-kit wild and on juxtamembrane activating mutations of Kit but it does not inhibit the 814 mutant c-kit.

20 Example 4 : Study of 37 new potential c-kit inhibitors.

We have tested 37 compounds that are indolinone derivatives in different cell lines and successive screening to select interesting inhibitors.

25 - **Method : select the compounds which are effectively c-kit inhibitors (Table 1)**

Each compound has been tested at a high dose (10 μ M) on cell expressing :

- c-kit carrying the 814 mutation
- SCF activated c-kit wild

WO 03/003006

PCT/IB02/03296

26

- control cells cultivated in IL-3.

Cells expressing c-kit carrying one of the juxtamembrane mutations ($\Delta 27$) were also used as a control.

- 5 **Results :** 21 compounds inhibit the 814 mutant c-kit : 6, 9, 10, 11, 14, 16, 17, 18, 19, 20, 21, 26, 28, 29, 30, 31, 32, 33, 34, 35 and 36.
- some compounds have poor inhibiting abilities on SCF activated c-kit: 7, 12, 13, 24, 25 and 27) : these compounds are consequently eliminated. The 21 compounds above are selected as being also active on SCF activated c-kit.
- 10 - 10 compounds are efficient on c-kit wild but not on 814 mutated c-kit : 1, 2, 3, 4, 5, 8, 15, 22, 23 and 37 (they supposedly don't act on the transphosphorylation domain of c-kit).

- 15 **Second selection :** selection within the 21 compounds of those who are active at lower doses (Figure 3)

The effect of the 21 inhibitors has been tested at decreasing concentrations ($10 - 10^{-1} - 10^{-2}$ μM) in order to reveal compounds that are able at $1\mu\text{M}$ to inhibit proliferation of the IC2 D814V line while preserving response to another stimulus (IL-3, toxicity control).

- 20 Nine inhibitors have been selected on the remaining 21 presenting interesting proliferation profiles : 10, 11, 14, 16, 17, 18, 19, 31 and 35.

Third selection : identification of the most efficient compounds (the most specific of 814 mutation) (Figure 4)

- 25 The nine compounds selected have been tested at narrower doses : between 0.1 and 1 μM . At this stage, the three most efficient compounds at lower doses have been selected ($\leq 0.6 \mu\text{M}$) : **11, 14 and 35.**

WO 03/003006

PCT/IB02/03296

27

Compound n°11 is a good candidate for therapeutic uses since it shows a weak activity on the IL-3 dependant cell line indicated that it is less toxic.

TABLE 2 : Proliferation test in presence of compounds at a dose of 10µM

5

Compound No	Ba/F3 Kit IL3	Ba/F3 Kit SCF	Ba/F3 Δ27	IC2 D814V
1	-	+	--	--
2	-	++	++	-
3	--	++	++	--
4	+ / -	++	+ / -	+ / -
5	-	+	-	+ / -
6	-	++	++	+ / -
7	--	+ / -	-	--
8	--	++	+	--
9	++	++	++	++
10	++	++	++	++
11	+	++	++	++
12	--	--	--	--
13	--	+ / -	--	--
14	++	++	++	++
15	-	++	++	-
16	++	++	++	++
17	++	++	++	++
18	++	++	++	++
19	++	++	++	++
20	++	++	++	++
21	++	++	++	++
22	--	+	++	-
23	--	++	+	--
24	--	-	--	--
25	--	+ / -	--	--
26	++	++	++	+
27	--	--	--	--
28	++	++	++	++
29	++	++	++	++
30	++	++	++	++

WO 03/003006

PCT/IB02/03296

28

31	++	++	++	++
32	++	++	++	++
33	++	++	++	++
34	++	++	++	++
35	++	++	++	++
36	++	++	++	++
37	+ / -	++	++	-

Table set up according to CPM (Counts Per Minutes) percentage obtained after proliferation in absence of inhibitors as 100 % (% CPM > 80 = -- / 50 < % CPM < 80 = - / 20 < % CPM < 50 = + / 5 < % CPM < 20 = + / % CPM < 5 = ++). All experiments
5 were done in triplicate.

Figure 1 presents a test of specificity versus toxicity (kit D814 versus kit + IL3) at low concentrations. These results show that compounds N°11 is non toxic at concentration efficient to inhibit SCF and mutant activated c-kit.

10

WO 03/003006

PCT/IB02/03296

References

1. Yarden, Y., Kuang, W., Yang-Feng, T., Coussens, L., Munemitsu, S., Düll, T., Chen, E., Schlessinger, J., Francke, U., Ullrich, A. (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. *EMBO J.* 6, 3341-3351.
2. d'Auriol, L., Mattei, M.G., Andre, C., Galibert, F. (1988) Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. *Hum. Genet.* 78, 374-376.
- 10 3. Matous, J., Langley, K., Kaushansky, K. (1996) Structure-function relationships of stem cell factor: an analysis based on a series of human-murine stem cell factor chimera and the mapping of a neutralizing monoclonal antibody. *Blood* 88, 437-444.
4. McNiece, I.K., Briddell, R.A. (1995) Stem cell factor. *J. Leukoc. Biol.* 58, 14-22.
5. Zsebo, K., Williams, D., Geissler, E., Broudy, V., Martin, F., Atkins, H., Hsu, R.,
15 Birkett, N., Okino, K., Murdock, D., et, a. (1990) Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. *Cell* 63, 213-224.
6. Flanagan, J.G., Leder, P. (1990) The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. *Cell* 63, 185-194.
- 20 7. Geissler, E.N., Liao, M., Brook, J.D., Martin, F.H., Zsebo, K.M., Housman, D.E., Galli, S.J. (1991) Stem cell factor (SCF), a novel hematopoietic growth factor and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter. *Somat. Cell. Mol. Genet.* 17, 207-214.
8. Anderson, D.M., Lyman, S.D., Baird, A., Wignall, J.M., Eisenman, J., Rauch, C.,
25 March, C.J., Boswell, H.S., Gimpel, S.D., Cosman, D., et al. (1990) Molecular cloning

WO 03/003006

PCT/IB02/03296

30

of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. *Cell* 63, 235-243.

9. Lev, S., Givol, D., Yarden, Y. (1991) A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. *EMBO J.* 10, 647-654.
- 5 10. Blechman, J.M., Lev, S., Barg, J., Eisenstein, M., Vaks, B., Vogel, Z., Givol, D., Yarden, Y. (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. *Cell* 80, 103-113.
11. Besmer, P., Murphy, J.E., George, P.C., Qiu, F.H., Bergold, P.J., Lederman, L., Snyder, H.W., Jr., Brodeur, D., Zuckerman, E.E., Hardy, W.D. (1986) A new acute
- 10 transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. *Nature* 320, 415-421.
12. Krystal, G.W., Hines, S.J., Organ, C.P. (1996) Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. *Cancer Res.* 56, 370-376.
13. Bellone, G., Silvestri, S., Artusio, E., Tibaudi, D., Turletti, A., Geuna, M., Giachino, C., Valente, G., Emanuelli, G., Rodeck, U. (1997) Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. *J. Cell. Physiol.* 172, 1-11.
14. Hines, S.J., Organ, C., Kornstein, M.J., Krystal, G.W. (1995) Coexpression of the c-kit and stem cell factor genes in breast carcinomas. *Cell Growth Differ.* 6, 769-779.
- 20 15. Inoue, M., Kyo, S., Fujita, M., Enomoto, T., Kondoh, G. (1994) Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. *Cancer Res.* 54, 3049-3053.
16. Cohen, P.S., Chan, J.P., Lipkunskaya, M., Biedler, J.L., Seeger, R.C. (1994) Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer
- 25 Group. *Blood* 84, 3465-3472.

WO 03/003006

PCT/IB02/03296

31

17. Metcalf, D. (1993) The cellular basis for enhancement interactions between stem cell factor and the colony stimulating factors. *Stem Cells (Dayt)* 11 Suppl 2, 1-11.
18. Ratajczak, M.Z., Luger, S.M., DeRiel, K., Abrahm, J., Calabretta, B., Gewirtz, A.M. (1992) Role of the KIT protooncogene in normal and malignant human hematopoiesis. *Proc. Natl. Acad. Sci. USA* 89, 1710-1714.
19. Katayama, N., Shih, J.P., Nishikawa, S., Kina, T., Clark, S.C., Ogawa, M. (1993) Stage-specific expression of c-kit protein by murine hematopoietic progenitors. *Blood* 82, 2353-2360.
20. Blume-Jensen, P., Siegbahn, A., Stabel, S., Heldin, C.H., Ronnstrand, L. (1993) Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. *EMBO J.* 12, 4199-4209.
21. Lev, S., Givol, D., Yarden, Y. (1992) Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. *Proc. Natl. Acad. Sci. USA* 89, 678-682.
22. Rottapel, R., Reedijk, M., Williams, D.E., Lyman, S.D., Anderson, D.M., Pawson, T., Bernstein, A. (1991) The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. *Mol. Cell. Biol.* 11, 3043-3051.
23. Serve, H., Hsu, Y.C., Besmer, P. (1994) Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit- associated PI 3-kinase activity in COS-1 cells. *J. Biol. Chem.* 269, 6026-6030.
24. Tauchi, T., Feng, G.S., Marshall, M.S., Shen, R., Mantel, C., Pawson, T., Broxmeyer, H.E. (1994) The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells. *J. Biol. Chem.* 269, 25206-25211.

WO 03/003006

PCT/IB02/03296

32

25. Feng, G.S., Ouyang, Y.B., Hu, D.P., Shi, Z.Q., Gentz, R., Ni, J. (1996) Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. *J. Biol. Chem.* 271, 12129-12132.
26. Brizzi, M.F., Dentelli, P., Lanfrancone, L., Rosso, A., Pelicci, P.G., Pegoraro, L. 5 (1996) Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation. *Oncogene* 13, 2067-2076.
27. Wisniewski, D., Strife, A., Clarkson, B. (1996) c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells. *Leukemia* 10, 1436-1442.
- 10 28. Sattler, M., Salgia, R., Shrikhande, G., Verma, S., Pisick, E., Prasad, K.V., Griffin, J.D. (1997) Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). *J. Biol. Chem.* 272, 10248-10253.
29. Blume-Jensen, P., Janknecht, R., Hunter, T. (1998) The kit receptor promotes cell 15 survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. *Curr. Biol.* 8, 779-782.
30. Tang, B., Mano, H., Yi, T., Ihle, J.N. (1994) Tec kinase associates with c-kit and is tyrosine phosphorylated and activated following stem cell factor binding. *Mol. Cell. Biol.* 14, 8432-8437.
- 20 31. Jhun, B.H., Rivnay, B., Price, D., Avraham, H. (1995) The MATK tyrosine kinase interacts in a specific and SH2-dependent manner with c-Kit. *J. Biol. Chem.* 270, 9661-9666.
32. Alai, M., Mui, A.L., Cutler, R.L., Bustelo, X.R., Barbacid, M., Krystal, G. (1992) 25 Steel factor stimulates the tyrosine phosphorylation of the proto-oncogene product, p95vav, in human hemopoietic cells. *J. Biol. Chem.* 267, 18021-18025.

WO 03/003006

PCT/IB02/03296

33

33. Carpino, N., Wisniewski, D., Strife, A., Marshak, D., Kobayashi, R., Stillman, B., Clarkson, B. (1997) p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. *Cell* 88, 197-204.
34. Brizzi, M., Zini, M., Aronica, M., Blechman, J., Yarden, Y., Pegoraro, L. (1994) 5 Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase. *J. Biol. Chem.* 269, 31680-31684.
35. Weiler, S.R., Mou, S., DeBerry, C.S., Keller, J.R., Ruscetti, F.W., Ferris, D.K., Longo, D.L., Linnekin, D. (1996) JAK2 is associated with the c-kit proto-oncogene 10 product and is phosphorylated in response to stem cell factor. *Blood* 87, 3688-3693.
36. Linnekin, D., Weiler, S.R., Mou, S., DeBerry, C.S., Keller, J.R., Ruscetti, F.W., Ferris, D.K., Longo, D.L. (1996) JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor. *Acta Haematol.* 95, 224-228.
37. Deberry, C., Mou, S., Linnekin, D. (1997) Stat1 associates with c-kit and is 15 activated in response to stem cell factor. *Biochem. J.* 327 (Pt 1), 73-80.
38. Herbst, R., Shearman, M.S., Jallal, B., Schlessinger, J., Ullrich, A. (1995) Formation of signal transfer complexes between stem cell and platelet- derived growth factor receptors and SH2 domain proteins in vitro. *Biochemistry* 34, 5971-5979.
39. Krystal, G.W., DeBerry, C.S., Linnekin, D., Litz, J. (1998) Lck associates with and 20 is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. *Cancer Res.* 58, 4660-4666.
40. Hemesath, T.J., Price, E.R., Takemoto, C., Badalian, T., Fisher, D.E. (1998) MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. *Nature* 391, 298-301.

WO 03/003006

PCT/IB02/03296

34

41. Takahira, H., Gotoh, A., Ritchie, A., Broxmeyer, H.E. (1997) Steel factor enhances integrin-mediated tyrosine phosphorylation of focal adhesion kinase (pp125FAK) and paxillin. *Blood* 89, 1574-1584.
42. Yi, T., Ihle, J.N. (1993) Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. *Mol. Cell. Biol.* 13, 3350-3358.
43. Lorenz, U., Bergemann, A.D., Steinberg, H.N., Flanagan, J.G., Li, X., Galli, S.J., Neel, B.G. (1996) Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. *J. Exp. Med.* 184, 1111-1126.
44. Paulson, R., Vesely, S., Siminovitch, K., Bernstein, A. (1996) Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. *Nat. Genet.* 13, 309-315.
45. Kozlowski, M., Larose, L., Lee, F., Le, D.M., Rottapel, R., Siminovitch, K.A. (1998) SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. *Mol. Cell. Biol.* 18, 2089-2099.
46. Blume-Jensen, P., Ronnstrand, L., Gout, I., Waterfield, M.D., Heldin, C.H. (1994) Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. *J. Biol. Chem.* 269, 21793-21802.
47. Blume-Jensen, P., Wernstedt, C., Heldin, C.H., Ronnstrand, L. (1995) Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells. *J. Biol. Chem.* 270, 14192-14200.
48. Kozawa, O., Blume-Jensen, P., Heldin, C.H., Ronnstrand, L. (1997) Involvement of phosphatidylinositol 3'-kinase in stem-cell-factor- induced phospholipase D activation and arachidonic acid release. *Eur. J. Biochem.* 248, 149-155.

WO 03/003006

PCT/IB02/03296

35

49. Timokhina, I., Kissel, H., Stella, G., Besmer, P. (1998) Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. *EMBO J.* 17, 6250-6262.
50. Suzuki, T., Shoji, S., Yamamoto, K., Nada, S., Okada, M., Yamamoto, T., Honda, Z. (1998) Essential roles of Lyn in fibronectin-mediated filamentous actin assembly and cell motility in mast cells. *J. Immunol.* 161, 3694-3701.
51. Koike, T., Mizutani, T., Hirai, K., Morita, Y., Nozawa, Y. (1993) SCF/c-kit receptor-mediated arachidonic acid liberation in rat mast cells. Involvement of PLD activation associated tyrosine phosphorylation. *Biochem. Biophys. Res. Commun.* 197, 10 1570-1577.
52. Koike, T., Hirai, K., Morita, Y., Nozawa, Y. (1993) Stem cell factor-induced signal transduction in rat mast cells. Activation of phospholipase D but not phosphoinositide-specific phospholipase C in c-kit receptor stimulation. *J. Immunol.* 151, 359-366.
53. Nagai, S., Kitani, S., Hirai, K., Takaishi, T., Nakajima, K., Kihara, H., Nonomura, Y., Ito, K., Morita, Y. (1995) Pharmacological study of stem-cell-factor-induced mast cell histamine release with kinase inhibitors. *Biochem. Biophys. Res. Commun.* 208, 15 576-581.
54. Yee, N., Hsiau, C., Serve, H., Vosseller, K., Besmer, P. (1994) Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3'-kinase, and protein kinase C. *J. Biol. Chem.* 269, 31991-31998.
55. Miyazawa, K., Toyama, K., Gotoh, A., Hendrie, P.C., Mantel, C., Broxmeyer, H.E. (1994) Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells. *Blood* 83, 137-145.

WO 03/003006

PCT/IB02/03296

36

56. Gommerman, J.L., Rottapel, R., Berger, S.A. (1997) Phosphatidylinositol 3-kinase and Ca²⁺ influx dependence for ligand- stimulated internalization of the c-Kit receptor. *J. Biol. Chem.* 272, 30519-30525.
57. De Sepulveda, P., Okkenhaug, K., Rose, J.L., Hawley, R.G., Dubreuil, P., Rottapel, R. (1999) Socs1 binds to multiple signalling proteins and suppresses Steel factor- dependent proliferation. *EMBO J.* 18, 904-915.
58. Blechman, J., Lev, S., Givol, D., Yarden, Y. (1993) Structure-function analyses of the kit receptor for the steel factor. *Stem Cells (Dayt)* 11 Suppl 2, 12-21.
59. Tsujimura, T. (1996) Role of c-kit receptor tyrosine kinase in the development, 10 survival and neoplastic transformation of mast cells. *Pathol. Int.* 46, 933-938.
60. Kitayama, H., Kanakura, Y., Furitsu, T., Tsujimura, T., Oritani, K., Ikeda, H., Sugahara, H., Mitsui, H., Kanayama, Y., Kitamura, Y., et al. (1995) Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. *Blood* 85, 790-798.
61. Tsujimura, T., Hashimoto, K., Kitayama, H., Ikeda, H., Sugahara, H., Matsumura, I., Kaisho, T., Terada, N., Kitamura, Y., Kanakura, Y. (1999) Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. *Blood* 93, 1319-1329.
62. Piao, X., Paulson, R., van der Geer, P., Pawson, T., Bernstein, A. (1996) 20 Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. *Proc. Natl. Acad. Sci. USA* 93, 14665-14669.
63. Songyang, Z., Shoelson, S.E., McGlade, J., Olivier, P., Pawson, T., Bustelo, X.R., Barbacid, M., Sabe, H., Hanafusa, H., Yi, T., et al. (1994) Specific motifs recognized by

WO 03/003006

PCT/IB02/03296

37

the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell. Biol. 14, 2777-2785.

64. Songyang, Z., Gish, G., Mbamalu, G., Pawson, T., Cantley, L.C. (1995) A single point mutation switches the specificity of group III Src homology (SH) 2 domains to that of group I SH2 domains. J. Biol. Chem. 270, 26029-26032.
65. Hofstra, R.M., Landsvater, R.M., Ceccherini, I., Stulp, R.P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J.W., van Amstel, H.K., Romeo, G., et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375-376.
66. Hanks, S.K., Quinn, A.M., Hunter, T. (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52.
67. Knighton, D.R., Zheng, J.H., Ten Eyck, L.F., Xuong, N.H., Taylor, S.S., Sowadski, J.M. (1991) Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 414-420.

15

WO 03/003006

PCT/IB02/03296

CLAIMS

1. A screening method for identifying compounds that are selective and potent inhibitors
5 of c-kit, which comprises :
 - a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,
 - b) selecting compounds that inhibit activated c-kit,
 - c) testing and selecting a subset of compounds identified in step b), which are unable to
10 promote death of IL-3 dependant cells cultured in presence of IL-3.
2. A screening method according to claim 1, wherein activated c-kit is an activated-mutant c-kit.
- 15 3. A screening method according to claim 2, further comprising the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant-activated c-kit, which are capable of inhibiting SCF-activated c-kit wild.
4. A screening method according to claim 1, wherein activated c-kit is SCF-activated c-
20 kit wild.
5. A screening method according to one of claims 1 to 4, wherein compounds in step a)
are tested at a concentration above 10 µM.
- 25 6. A screening method according to one of claims 1 to 4, wherein IL-3 is present in the culture media of IL-3 dependant cells at a concentration comprised between 0.5 and 10 ng/ml.

WO 03/003006

PCT/IB02/03296

39

7. A screening method according to claim 6, wherein IL-3 is present in the culture media of IL-3 dependant cells at a concentration comprised between 1 to 5 ng/ml.
8. A screening method according to one of claims 6 and 7, wherein IL-3 dependant cells
5 are selected from the group consisting of mast cells, transfected mast cells, BaF3 and IC-2.
9. A screening method according to claim 1 to 3, wherein the activated-mutant c-kit in
step a) has at least one mutation proximal to Y823, more particularly between amino
10 acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants.
10. A screening method according one of claims 1 to 9, wherein the extent to which
component (ii) inhibits activated c-kit is measured *in vitro* or *in vivo*.
15
11. A screening method according one of claims 1 to 10, further comprising the step
consisting of testing and selecting compounds capable of inhibiting c-kit wild at
concentration below 1 μ M.
- 20 12. A screening method according to claim 11, wherein the extent to which said
compounds inhibit c-kit wild is measured *in vitro* or *in vivo*.
13. A screening method according to claim 11, wherein said compounds are potent,
selective and non-toxic c-kit wild inhibitors.
25
14. A screening method according to one of claims 1 to 13, wherein said inhibitors act
on the transphosphorylation domain of c-kit wild.

WO 03/003006

PCT/IB02/03296

40

15. A screening method for identifying compounds that are selective and potent inhibitors of c-kit, which comprises :

- i) addition of chemical groups responsible for the inhibition of c-kit autophosphorylation
5 to compounds identified by the method according to claim 4,
ii) testing and selecting a subset of compounds identified in step i), which inhibit activated-mutant c-kit.

16. A screening method according to one of claims 1 to 15, wherein the inhibition of
10 mutant-activated c-kit and/or c-kit wild is measuring by the amount the c-kit phosphorylation.

17. A screening method according to claim 1 for identifying potent and selective compounds that are inhibitors of c-kit comprising :

- 15 a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an IC₅₀ < 10 μM, by measuring the extent of cell death,
b) performing a proliferation assay with cells expressing c-kit wild said subset of
20 candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,
c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an IC₅₀ < 10 μM, preferably an IC₅₀ < 1 μM, by measuring the extent of cell death.
25

WO 03/003006

PCT/IB02/03296

41

18. A screening method according to claim 17, wherein the extent of cell death is measured by ^3H thymidine incorporation, the trypan blue exclusion method or flow cytometry with propidium iodide.
- 5 19. A screening method according to one of claims 1 to 18, wherein said compounds are tyrosine kinase inhibitors.
- 10 20. A screening method according to one of claims 1 to 19, wherein said compounds are selected from the group consisting of indolinone, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, , seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.
- 15 21. A screening method according to one of claims 1 to 19, wherein said compounds are pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives.
- 20 22. A screening method according to one of claims 1 to 19, wherein said compounds are indolinone derivatives, more particularly pyrrol-substituted indolinones.
- 25 23. A screening method according to one of claims 1 to 19, wherein said compounds are monocyclic, bicyclic aryl and heteroaryl compounds.
- 25 24. A screening method according to one of claims 1 to 19, wherein said compounds are quinazoline derivatives.

WO 03/003006**PCT/IB02/03296****42**

25. A compound obtainable by the method according to one of claims 1 to 24, wherein said compound is a selective and potent inhibitor of activated c-kit, a potent inhibitors of c-kit wild acting in the transphosphorylation domain and is unable to promote death of IL-3 dependant cells cultured in presence of IL-3.

5

26. Use of a compound according to claim 25 to manufacture a medicament.

WO 03/003006

PCT/IB02/03296

1 / 1




FIGURE 1

WO 03/003006

PCT/IB02/03296

1/5

SEQUENCE LISTING

<110> AB Science

<110> Institut National de la Santé et de la Recherche Médicale (INSERM)

<110> Université René Descartes Paris 5

<120> New potent, selective and non toxic c-kit inhibitors

<130> D19700 NT

<150> US 60/301,404

<151> 2001-06-29

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 976

<212> PRT

<213> Homo sapiens

<220>

<223> Human c-kit

<400> 1

Met	Arg	Gly	Ala	Arg	Gly	Ala	Trp	Asp	Phe	Leu	Cys	Val	Leu	Leu	Leu
1					5					10					15

Leu	Leu	Arg	Val	Gln	Thr	Gly	Ser	Ser	Gln	Pro	Ser	Val	Ser	Pro	Gly
			20				25					30			

Glu	Pro	Ser	Pro	Pro	Ser	Ile	His	Pro	Gly	Lys	Ser	Asp	Leu	Ile	Val
35							40					45			

Arg	Val	Gly	Asp	Glu	Ile	Arg	Leu	Leu	Cys	Thr	Asp	Pro	Gly	Phe	Val
50					55					60					

Lys	Trp	Thr	Phe	Glu	Ile	Leu	Asp	Glu	Thr	Asn	Glu	Asn	Gln	Asn	
65					70				75				80		

Glu	Trp	Ile	Thr	Glu	Lys	Ala	Glu	Ala	Thr	Asn	Thr	Gly	Lys	Tyr	Thr
				85					90				95		

Cys	Thr	Asn	Lys	His	Gly	Leu	Ser	Asn	Ser	Ile	Tyr	Val	Phe	Val	Arg
						100			105			110			

Asp	Pro	Ala	Lys	Leu	Phe	Leu	Val	Asp	Arg	Ser	Leu	Tyr	Gly	Lys	Glu
					115		120					125			

Asp	Asn	Asp	Thr	Leu	Val	Arg	Cys	Pro	Leu	Thr	Asp	Pro	Glu	Val	Thr
					130		135			140					

Asn	Tyr	Ser	Leu	Lys	Gly	Cys	Gln	Gly	Lys	Pro	Leu	Pro	Lys	Asp	Leu
145									155				160		

Arg	Phe	Ile	Pro	Asp	Pro	Lys	Ala	Gly	Ile	Met	Ile	Lys	Ser	Val	Lys
						165			170			175			

WO 03/003006

PCT/IB02/03296

2/5

Arg Ala Tyr His Arg Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly
180 185 190

Lys Ser Val Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe
195 200 205

Lys Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg
210 215 220

Glu Gly Glu Glu Phe Thr Val Thr Cys Thr Ile Lys Asp Val Ser Ser
225 230 235 240

Ser Val Tyr Ser Thr Trp Lys Arg Glu Asn Ser Gln Thr Lys Leu Gln
245 250 255

Glu Lys Tyr Asn Ser Trp His His Gly Asp Phe Asn Tyr Glu Arg Gln
260 265 270

Ala Thr Leu Thr Ile Ser Ser Ala Arg Val Asn Asp Ser Gly Val Phe
275 280 285

Met Cys Tyr Ala Asn Asn Thr Phe Gly Ser Ala Asn Val Thr Thr Thr
290 295 300

Leu Glu Val Val Asp Lys Gly Phe Ile Asn Ile Phe Pro Met Ile Asn
305 310 315 320

Thr Thr Val Phe Val Asn Asp Gly Glu Asn Val Asp Leu Ile Val Glu
325 330 335

Tyr Glu Ala Phe Pro Lys Pro Glu His Gln Gln Trp Ile Tyr Met Asn
340 345 350

Arg Thr Phe Thr Asp Lys Trp Glu Asp Tyr Pro Lys Ser Glu Asn Glu
355 360 365

Ser Asn Ile Arg Tyr Val Ser Glu Leu His Leu Thr Arg Leu Lys Gly
370 375 380

Thr Glu Gly Gly Thr Tyr Thr Phe Leu Val Ser Asn Ser Asp Val Asn
385 390 395 400

Ala Ala Ile Ala Phe Asn Val Tyr Val Asn Thr Lys Pro Glu Ile Leu
405 410 415

Thr Tyr Asp Arg Leu Val Asn Gly Met Leu Gln Cys Val Ala Ala Gly
420 425 430

Phe Pro Glu Pro Thr Ile Asp Trp Tyr Phe Cys Pro Gly Thr Glu Gln
435 440 445

Arg Cys Ser Ala Ser Val Leu Pro Val Asp Val Gln Thr Leu Asn Ser
450 455 460

Ser Gly Pro Pro Phe Gly Lys Leu Val Val Gln Ser Ser Ile Asp Ser
465 470 475 ; 480

Ser Ala Phe Lys His Asn Gly Thr Val Glu Cys Lys Ala Tyr Asn Asp
485 490 495

Val Gly Lys Thr Ser Ala Tyr Phe Asn Phe Ala Phe Lys Gly Asn Asn

WO 03/003006

PCT/IB02/03296

3/5

500

505

510

Lys Glu Gln Ile His Pro His Thr Leu Phe Thr Pro Leu Leu Ile Gly
 515 520 525

Phe Val Ile Val Ala Gly Met Met Cys Ile Ile Val Met Ile Leu Thr
 530 535 540

Tyr Lys Tyr Leu Gln Lys Pro Met Tyr Glu Val Gln Trp Lys Val Val
 545 550 555 560

Glu Glu Ile Asn Gly Asn Asn Tyr Val Tyr Ile Asp Pro Thr Gln Leu
 565 570 575

Pro Tyr Asp His Lys Trp Glu Phe Pro Arg Asn Arg Leu Ser Phe Gly
 580 585 590

Lys Thr Leu Gly Ala Gly Ala Phe Gly Lys Val Val Glu Ala Thr Ala
 595 600 605

Tyr Gly Leu Ile Lys Ser Asp Ala Ala Met Thr Val Ala Val Lys Met
 610 615 620

Leu Lys Pro Ser Ala His Leu Thr Glu Arg Glu Ala Leu Met Ser Glu
 625 630 635 640

Leu Lys Val Leu Ser Tyr Leu Gly Asn His Met Asn Ile Val Asn Leu
 645 650 655

Leu Gly Ala Cys Thr Ile Gly Gly Pro Thr Leu Val Ile Thr Glu Tyr
 660 665 670

Cys Cys Tyr Gly Asp Leu Leu Asn Phe Leu Arg Arg Lys Arg Asp Ser
 675 680 685

Phe Ile Cys Ser Lys Gln Glu Asp His Ala Glu Ala Ala Leu Tyr Lys
 690 695 700

Asn Leu Leu His Ser Lys Glu Ser Ser Cys Ser Asp Ser Thr Asn Glu
 705 710 715 720

Tyr Met Asp Met Lys Pro Gly Val Ser Tyr Val Val Pro Thr Lys Ala
 725 730 735

Asp Lys Arg Arg Ser Val Arg Ile Gly Ser Tyr Ile Glu Arg Asp Val
 740 745 750

Thr Pro Ala Ile Met Glu Asp Asp Glu Leu Ala Leu Asp Leu Glu Asp
 755 760 765

Leu Leu Ser Phe Ser Tyr Gln Val Ala Lys Gly Met Ala Phe Leu Ala
 770 775 780

Ser Lys Asn Cys Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu
 785 790 795 800

Thr His Gly Arg Ile Thr Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp
 805 810 815

Ile Lys Asn Asp Ser Asn Tyr Val Val Lys Gly Asn Ala Arg Leu Pro
 820 825 830

WO 03/003006

PCT/IB02/03296

4/5

Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asn Cys Val Tyr Thr Phe
 835 840 845

Glu Ser Asp Val Trp Ser Tyr Gly Ile Phe Leu Trp Glu Leu Phe Ser
 850 855 860

Leu Gly Ser Ser Pro Tyr Pro Gly Met Pro Val Asp Ser Lys Phe Tyr
 865 870 875 880

Lys Met Ile Lys Glu Gly Phe Arg Met Leu Ser Pro Glu His Ala Pro
 885 890 895

Ala Glu Met Tyr Asp Ile Met Lys Thr Cys Trp Asp Ala Asp Pro Leu
 900 905 910

Lys Arg Pro Thr Phe Lys Gln Ile Val Gln Leu Ile Glu Lys Gln Ile
 915 920 925

Ser Glu Ser Thr Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro
 930 935 940

Asn Arg Gln Lys Pro Val Val Asp His Ser Val Arg Ile Asn Ser Val
 945 950 955 960

Gly Ser Thr Ala Ser Ser Gln Pro Leu Leu Val His Asp Asp Val
 965 970 975

<210> 2
<211> 30
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 2
aagaagagat ggtacctcga ggggtgaccc

30

<210> 3
<211> 33
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 3
ctgcttcgcg gccgcgttaa ctcttctcaa cca

33

<210> 4
<211> 20
<212> DNA
<213> Homo sapiens

WO 03/003006**PCT/IB02/03296****5/5**

<220>
<223> Primer

<400> 4
agctcggtta gtgaaccgtc

20

<210> 5
<211> 20
<212> DNA
<213> Homo sapiens

<220>
<223> Primer

<400> 5
gtcagacaaa atgatgcaac

20